Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment
about
Chimeric Antigen Receptors Modified T-Cells for Cancer TherapyInnate and adaptive immune cells in the tumor microenvironmentNKG2D ligands as therapeutic targetsCAR therapy: the CD19 paradigmEngineered T cells for cancer treatmentNKG2D CARs as cell therapy for cancer.NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand- Dependent Manner in Systemic Lupus Erythematosus.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsTargeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles.NK cells: immune cross-talk and therapeutic implications.Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsPeripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.Chimeric Antigen Receptor T-Cell Therapy for the Community OncologistNKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.Cbx3/HP1γ deficiency confers enhanced tumor-killing capacity on CD8+ T cells.γδ T cells as a potential tool in colon cancer immunotherapy.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.
P2860
Q26773309-2299F860-AF2C-421A-A434-B5260D685492Q27008342-6A3CEAD3-CC20-4D78-8E28-959F23AE2750Q27014888-534DEE15-CB7A-4769-B7DE-323AB1B3952AQ28081642-0888EF7F-8396-4C6E-938E-D0AE4A515A55Q33578792-DFBDE53A-8E67-4053-B1D4-1D876D9D657BQ33595873-9FCCF3C9-2AA1-4426-8648-2456061F34D4Q33682274-27381A90-5299-4B6F-82B6-861A83ECE062Q34557233-A1F9D433-887E-4DDE-89EB-37611BF89B62Q34786615-A379DF25-2A99-4C3E-9056-7548FCB4B74AQ34983200-E5005ACE-D40E-4047-BD1B-301413BD8DB8Q34985537-1BA56494-FA10-4094-AD4E-80CFE35A05A1Q35168522-77791AAF-C668-40B4-BC18-65B63C607E20Q35591444-F4F12BB9-FF71-410B-A3A4-C0D8EF18A941Q36016640-765DCDD4-A3DB-4EA6-BD3F-E8AB37DCB1F3Q36244004-2FD26072-1600-4402-A030-B1DFBD3CE5F0Q36470354-3B62AD18-9DBC-48CA-A0B0-AC1AE6B245F9Q36833481-9DA96E2C-31F6-4355-AA58-8AF7A3F820B0Q36845800-ECF3D58F-F0DA-4249-B577-11DE203C8036Q36884399-01867AF8-7F10-4459-86A1-B617727D37BEQ36980241-FFADA6E3-87E0-4043-AF74-B4CAB46CD816Q37654781-D73DF371-A900-48B7-A432-D04EE5BCE2ECQ38262257-91BA88BB-46CE-429D-A268-B62821A8FD1DQ38730881-81570630-BE1C-4EB1-9019-53E9D8ABAA23Q38830813-6889489E-6356-41A5-8DBE-978BF8AFE311Q39160959-850D530E-C4C2-4177-B78D-29375EB8568FQ39203569-81C95DD1-4EBA-4632-AAFE-77F56D4F097CQ39525496-733CB23A-981D-408D-852B-31352A6FC94EQ39790928-8573EF4E-46BD-4E79-BE4B-C2114C02C8B7Q47111488-17F1028C-C074-479C-9720-7EA833D3C1C5Q47159409-680DC763-9A98-404C-AA24-2C3AFE03A933Q47216941-E1329A13-B2F2-49A7-B590-EFAC2ECCBF11Q47849932-FCCF18B5-2CDE-4769-8FF4-49994B9DAF67
P2860
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@ast
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@en
type
label
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@ast
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@en
prefLabel
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@ast
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@en
P2093
P2860
P356
P1476
Chimeric NKG2D expressing T ce ...... ovarian tumor microenvironment
@en
P2093
Agnieszka Rynda
Amorette Barber
Charles L Sentman
P2860
P304
P356
10.4049/JIMMUNOL.0902000
P407
P577
2009-11-13T00:00:00Z